Therefore, over the past few decades, NSCLC treatment has evolved from the use of cytotoxic drugs to the use of personalized regimens targeting particular molecular targets such as anaplastic lymphoma kinase (ALK), epidermal growth factor receptor (EGFR), ROS1, vascular endothelial growth factor receptor (VEGFR), human epidermal growth factor receptor-2 (HER2), and Kirsten ras sarcoma (KRAS) 4. This evidence concerns the gene KRAS and non-small cell lung carcinoma.